非侵入性临床蛋白质组学实现自身免疫性肝炎的诊断
研究纳入19例新诊断自身免疫性肝炎(AIH)、17例代谢功能障碍相关脂肪性肝病(MASLD)和19例健康对照,对肝组织和血浆行非靶向质谱蛋白质组学并用逻辑回归机器学习分类。血浆蛋白质组区分AIH与MASLD及健康对照的AUC为0.91(0.09 SD),20个诊断蛋白中8个在英国生物银行验证显示方向一致;作者认为蛋白质组学可能成为AIH新型非侵入性诊断工具,但需在更大、年龄和性别匹配的队列中验证。
要点
- 肝组织和血浆蛋白质组学可区分AIH与MASLD及健康对照,血浆AUC为0.91(0.09 SD)。
- AIH肝脏蛋白质组以代谢失调为特征,血浆蛋白质组以系统性免疫激活为特征。
- 20个诊断蛋白中8个在英国生物银行验证方向一致,C7、ICAM1、cAST在校正年龄和性别后仍显著不同。
核心结论
- 对AIH患者配对的肝-血浆样本行临床蛋白质组学分析显示出高诊断潜力,若在更大、年龄和性别匹配的队列中得到验证,蛋白质组学可能成为AIH的新型非侵入性诊断工具。
研究设计与样本
- 研究招募19例新诊断AIH患者、17例MASLD患者和19例健康对照,采集肝组织和血浆行非靶向质谱蛋白质组学,并对肝和血浆蛋白质组数据采用逻辑回归模型进行机器学习分析以分类AIH与MASLD及健康对照。
- 研究结果利用英国生物银行(UKB)数据进行验证。
主要发现
- 鉴定出7632个肝脏蛋白和556个血浆蛋白,其中2521个肝脏蛋白和227个血浆蛋白在AIH与健康对照间存在差异,包括56个重叠蛋白。
- AIH肝脏蛋白质组以代谢失调为特征,血浆蛋白质组以系统性免疫激活为特征。
- 血浆蛋白质组分析区分AIH与MASLD及健康对照的受试者工作特征曲线下面积为0.91(0.09 SD)。
- 20个诊断蛋白中8个可在UKB中验证,并显示一致的方向性变化。
- 未校正分析中3个蛋白(C7、ICAM1、cAST)在AIH与MASLD/健康对照间显著不同,校正年龄和性别后8个蛋白中6个(C7、ICAM1、cAST、IGFBP3、TIMP1、TTR)显著不同。
局限性
- 作者指出需在更大、年龄和性别匹配的队列中验证后,蛋白质组学才可能成为AIH的新型非侵入性诊断工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autoimmune hepatitis (AIH) may be difficult to diagnose and distinguish clinically and biochemically from other chronic liver diseases like metabolic dysfunction-associated steatotic liver disease (MASLD). AIMS: To identify pathways involved in the pathogenesis and identify disease-specific biomarkers of AIH. METHODS: We recruited 19 newly diagnosed patients with AIH, 17 with MASLD, and 19 healthy controls. Liver tissue and plasma were collected, and untargeted mass-spectrometry-based proteomics was performed. For classification of AIH versus MASLD and healthy, machine learning analyses were performed employing logistic regression models on liver and plasma proteome data. Findings were validated using data from the United Kingdom Biobank (UKB). RESULTS: We identified 7632 liver and 556 plasma proteins with 2521 liver and 227 plasma proteins differing between AIH and healthy, including 56 overlapping. Metabolic dysregulation and systemic immune activation characterised the AIH liver and plasma proteome, respectively. Plasma proteome profiling enabled classification of AIH from MASLD and healthy with an area under the receiver operating characteristic curve of 0.91 (0.09 SD). Validation in the UKB was possible for 8 of 20 diagnostic proteins and showed consistent directional changes. Three proteins (C7, ICAM1, cAST) were significantly different between AIH and MASLD/healthy in unadjusted analyses, and 6 of 8 proteins (C7, ICAM1, cAST, IGFBP3, TIMP1, TTR) were significantly different when adjusting for age and sex. CONCLUSIONS: Clinical proteomic analyses of paired liver-plasma samples from patients with AIH enabled high diagnostic potential. Proteomics may constitute a novel non-invasive diagnostic tool for AIH if validated in larger, age- and sex-matched cohorts. CLINICAL TRIAL NUMBER: NCT05335603.
引用
- Jensen AH, Ytting H, Nielsen AB, et al. Diagnostics of Autoimmune Hepatitis Enabled by Non-Invasive Clinical Proteomics. Aliment Pharmacol Ther. 2025. PMID: 40671462. doi:10.1111/apt.70273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。